Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

IGC Pharma stock price, quote, forecast and news

IGC
US45408X3089
A1T87A

Price

0.35
Today +/-
+0.01
Today %
+2.53 %
P

IGC Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the IGC Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the IGC Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the IGC Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze IGC Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

IGC Pharma Stock Price History

DateIGC Pharma Price
9/19/20240.35 undefined
9/18/20240.34 undefined
9/17/20240.35 undefined
9/16/20240.35 undefined
9/13/20240.36 undefined
9/12/20240.36 undefined
9/11/20240.37 undefined
9/10/20240.37 undefined
9/9/20240.37 undefined
9/6/20240.35 undefined
9/5/20240.35 undefined
9/4/20240.35 undefined
9/3/20240.35 undefined
8/30/20240.36 undefined
8/29/20240.35 undefined
8/28/20240.36 undefined
8/27/20240.35 undefined
8/26/20240.36 undefined
8/23/20240.37 undefined
8/22/20240.38 undefined

IGC Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IGC Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IGC Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IGC Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IGC Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IGC Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IGC Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IGC Pharma’s growth potential.

IGC Pharma Revenue, EBIT and net profit per share

DateIGC Pharma RevenueIGC Pharma EBITIGC Pharma Net Income
2027e1.52 M undefined-12.8 M undefined-6.7 M undefined
2026e1.53 M undefined-10.61 M undefined-7.55 M undefined
2025e1.35 M undefined-9.86 M undefined-7.93 M undefined
20241.35 M undefined-8.8 M undefined-13 M undefined
2023910,000 undefined-11.19 M undefined-11.51 M undefined
2022400,000 undefined-10.68 M undefined-15.02 M undefined
2021900,000 undefined-8.72 M undefined-8.81 M undefined
20204.07 M undefined-6.87 M undefined-7.32 M undefined
20195.12 M undefined-4.64 M undefined-4.1 M undefined
20182.19 M undefined-1.79 M undefined-1.79 M undefined
2017580,000 undefined-2.05 M undefined-1.87 M undefined
20166.37 M undefined-2.59 M undefined-2.81 M undefined
20157.68 M undefined-4.34 M undefined-4.61 M undefined
20142.27 M undefined-2.51 M undefined-3.02 M undefined
20138.03 M undefined-2.18 M undefined-2.25 M undefined
20124.2 M undefined-6.32 M undefined-7.75 M undefined
20114.07 M undefined-7.91 M undefined-20.24 M undefined
201017.9 M undefined-3.99 M undefined-4.79 M undefined
200935.34 M undefined2.31 M undefined-520,000 undefined
20082.19 M undefined-20,000 undefined-5.22 M undefined
20070 undefined0 undefined1.52 M undefined
20060 undefined-530,000 undefined-440,000 undefined

IGC Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
002351744827602540001111
---1,650.00-51.43-76.47-100.00-75.00250.00-14.29--150.00-20.00-------
---22.8611.76--12.50--------------
0008200100000000000000
0002-3-7-6-2-2-4-2-2-1-4-6-8-10-11-8-9-10-12
---5.71-17.65-175.00-150.00-25.00-100.00-57.14-33.33--50.00-80.00-150.00----800.00-900.00-1,000.00-1,200.00
01,000-5,0000-4,000-20,000-7,000-2,000-3,000-4,000-2,000-1,000-1,000-4,000-7,000-8,000-15,000-11,000-13,000-7,000-7,000-6,000
---600.00--400.00-65.00-71.4350.0033.33-50.00-50.00-300.0075.0014.2987.50-26.6718.18-46.15--14.29
1.41.40.861.011.151.512.916.978.2114.7616.3925.6627.9435.3939.4941.9649.9952.5858.84000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The IGC Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IGC Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2006200720082009201020112012201320142015201620172018201920202021202220232024
                                     
65.8370.2711.42.130.841.580.561.061.030.821.492.421.6625.6112.3414.6310.463.351.2
0015.2912.367.93.311.641.070.570.990.960.750.560.080.130.180.130.110.04
00.040.280000000000001.740.470.020.05
001.552.120.160.130.390.410.610.710.1600.490.254.255.483.552.651.54
0.080.074.382.892.21.522.631.731.561.951.230.410.50.781.041.50.510.330.88
65.9170.3832.919.511.16.545.224.273.774.473.843.583.2126.7217.7623.5315.126.463.7
007.346.61.751.238.498.187.597.787.070.956.245.8910.3511.339.878.543.89
001.690.079.257.315.755.195.146.035.786.010.80.790.010.01000
003.522.77000000000000000
0000003.840.590.470.310.1100.130.180.250.410.921.171.62
0017.4817.486.150.410.97000.981.180.20000000
0.030.34.75.417.122.6711.010.780.750.860.540.480.880.610.60.9410.69
0.030.334.7332.3324.2711.6220.0514.9713.9815.85157.77.657.7411.2212.3511.7310.716.2
65.9470.6867.6351.8335.3718.1625.2719.2417.7520.3218.8411.2810.8634.4628.9835.8826.8517.179.9
                                     
12.7612.760003.080.0100000000109.72116.02118.97124.41
50.6151.8531.4733.1936.8138.8654.8256.1558.3663.4865.8961.4163.9194.0494.750000
-0.441.07-4.14-4.66-9.45-29.69-37.44-39.7-42.72-47.33-50.14-52.01-53.8-58.05-65.37-74.14-89.16-100.67-113.67
000-4.93-2.58-2.5-2.54-2.02-2.02-1.91-2.27-2.05-2.06-2.42-2.85-2.77-2.97-3.39-3.42
0000000000000000000
62.9365.6827.3323.624.789.7514.8514.4313.6214.2413.487.358.0533.5726.5332.8123.8914.917.32
003.11.681.991.310.650.60.130.170.330.420.050.320.760.480.980.530.77
0.290.241.370.560.550.431.030.520.430.910.820.1800.510.510.941.180.750.94
1.842.14.282.270.060.020.590.260.050.010.030.690.4900.620.650.280.610.62
0.872.668.644.945.514.822.232.250.421.352.0201.8000000
00000000000005050300003
3517.399.458.116.584.53.631.032.443.21.292.340.881.942.372.441.892.34
001.211.500001.82.120.82.640.43000.280.140.140.14
0061059000710000000000000
007.552.441.111.214.230.650.761.010.9100.010.020.50.420.360.230.1
009.374.531.111.214.940.652.563.131.712.640.440.020.50.70.50.370.24
3526.7613.989.227.799.444.283.595.574.913.932.780.92.443.072.942.262.58
65.9370.6854.0937.583417.5424.2918.7117.2119.8118.3911.2810.8334.4728.9735.8826.8317.179.9
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IGC Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IGC Pharma's financial health and stability.

Assets

IGC Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IGC Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IGC Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IGC Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200620072008200920102011201220132014201520162017201820192020202120222023
01,000-5,0000-4,000-21,000-7,000-2,000-3,000-4,000-2,000-1,000-1,000-4,000-7,000-8,000-15,000-11,000
0000001,00000000000000
0000-34000000000000
00-4-10-1000001000-3-320
0-320613111100001043
001,0001,00000000000000000
000000000000000000
0-1-8-8-1-2-50-1-20-1-1-3-8-10-7-7
000-2-1000000000-4-100
-650572-2040000000-9300
-6505750040000000-5400
000000000000000000
03-4-1100000000-10000
680-3301300121032901440
653-4102300121032701440
-4.00--3.00---------------
000000000000000000
017-6-10-100000123-187-4-7
-0.1-1.56-8.57-10.6-3.19-2.92-5.03-0.15-1.75-2.66-0.28-1.54-2.13-3.39-13.15-12.39-8.2-7.67
000000000000000000

IGC Pharma stock margins

The IGC Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IGC Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IGC Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IGC Pharma's sales revenue. A higher gross margin percentage indicates that the IGC Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IGC Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IGC Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IGC Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IGC Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IGC Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IGC Pharma Margin History

IGC Pharma Gross marginIGC Pharma Profit marginIGC Pharma EBIT marginIGC Pharma Profit margin
2027e54.5 %-845 %-442.29 %
2026e54.5 %-693.72 %-493.95 %
2025e54.5 %-728.42 %-586.44 %
202454.5 %-654.13 %-966.54 %
202348.35 %-1,229.67 %-1,264.84 %
202247.5 %-2,670 %-3,755 %
202112.22 %-968.89 %-978.89 %
20202.95 %-168.8 %-179.85 %
20192.54 %-90.63 %-80.08 %
20183.65 %-81.74 %-81.74 %
201737.93 %-353.45 %-322.41 %
201613.19 %-40.66 %-44.11 %
20157.55 %-56.51 %-60.03 %
201416.74 %-110.57 %-133.04 %
201319.05 %-27.15 %-28.02 %
2012-14.76 %-150.48 %-184.52 %
20113.93 %-194.35 %-497.3 %
201012.46 %-22.29 %-26.76 %
200923.09 %6.54 %-1.47 %
200818.72 %-0.91 %-238.36 %
200754.5 %0 %0 %
200654.5 %0 %0 %

IGC Pharma Stock Sales Revenue, EBIT, Earnings per Share

The IGC Pharma earnings per share therefore indicates how much revenue IGC Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IGC Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IGC Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IGC Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IGC Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IGC Pharma Revenue, EBIT and net profit per share

DateIGC Pharma Sales per ShareIGC Pharma EBIT per shareIGC Pharma Earnings per Share
2027e0.02 undefined0 undefined-0.09 undefined
2026e0.02 undefined0 undefined-0.1 undefined
2025e0.02 undefined0 undefined-0.1 undefined
20240.02 undefined-0.15 undefined-0.22 undefined
20230.02 undefined-0.21 undefined-0.22 undefined
20220.01 undefined-0.21 undefined-0.3 undefined
20210.02 undefined-0.21 undefined-0.21 undefined
20200.1 undefined-0.17 undefined-0.19 undefined
20190.14 undefined-0.13 undefined-0.12 undefined
20180.08 undefined-0.06 undefined-0.06 undefined
20170.02 undefined-0.08 undefined-0.07 undefined
20160.39 undefined-0.16 undefined-0.17 undefined
20150.52 undefined-0.29 undefined-0.31 undefined
20140.28 undefined-0.31 undefined-0.37 undefined
20131.15 undefined-0.31 undefined-0.32 undefined
20121.44 undefined-2.17 undefined-2.66 undefined
20112.7 undefined-5.24 undefined-13.4 undefined
201015.57 undefined-3.47 undefined-4.17 undefined
200934.99 undefined2.29 undefined-0.51 undefined
20082.55 undefined-0.02 undefined-6.07 undefined
20070 undefined0 undefined1.09 undefined
20060 undefined-0.38 undefined-0.31 undefined

IGC Pharma business model

India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma is one of the most popular companies on Eulerpool.com.

IGC Pharma SWOT Analysis

Strengths

India Globalization Capital Inc (IGC) possesses a strong global presence and has successfully expanded its operations internationally. This allows the company to tap into emerging markets and diversify its revenue streams.

IGC has a robust portfolio of intellectual property rights and patents, enabling it to protect its innovations and maintain a competitive advantage in the market.

The company has a strong research and development (R&D) team, which consistently develops innovative solutions and products. This drives IGC's growth and positions it as a leader in its industry.

Weaknesses

One weakness of IGC is its dependency on key suppliers for raw materials and components. Any disruption or delays in the supply chain could negatively impact the company's operations and profitability.

Another weakness is IGC's limited financial resources. This may constrain its ability to invest in large-scale projects or seize growth opportunities.

Additionally, IGC faces regulatory challenges in certain markets where it operates. Compliance with different regulations and standards can be complex and costly, affecting the company's ability to expand in those regions.

Opportunities

IGC has the opportunity to capitalize on the growing demand for its products and services in emerging markets, especially in industries such as infrastructure development and alternative energy.

The company can explore strategic partnerships and collaborations with other industry leaders to enhance its product offerings and expand its market reach.

Furthermore, the increasing government focus on sustainability and renewable energy provides IGC with opportunities to develop and market eco-friendly solutions.

Threats

One of the main threats facing IGC is intense competition from both domestic and international players. The industry is characterized by rapid technological advancements and evolving customer needs.

Macroeconomic factors, such as exchange rate fluctuations and economic downturns, can significantly impact IGC's financial performance and market stability.

Moreover, changing government regulations and policies related to intellectual property rights and environmental standards pose threats to IGC's operations and market positioning.

IGC Pharma Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IGC Pharma Revenue by Segment

Segmente20202019
Purchase and Resale of Physical Commodities3.55 M USD-
Wellness and Lifestyle386,000 USD-
Construction101,000 USD-
Tolling/White labeling service25,000 USD-
Rental Income7,000 USD-
--
Legacy Infrastructure3.66 M USD5.09 M USD
Purchase and Resale of Physical Commodities-5.06 M USD
Plant and Cannabinoid411,000 USD25,000 USD
Rental Income-30,000 USD
Cannabinoid Products and Therapies-25,000 USD
Construction Contracts--
Alternative Therapies--
Legacy Business--
Rental/Lease--
Trading, electronic component--
Trading--
Construction--
Legacy Infrastructure-5.09 M USD
Asia-70,000 USD
Plant and Cannabinoid-25,000 USD
Life Sciences411,000 USD-

IGC Pharma Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

IGC Pharma Revenue by Segment

DateAsiaCOLOMBIAHONG KONGINDIANorth AmericaUnited States
2024--2,000 USD-164,000 USD-1.18 M USD
2022329,000 USD---68,000 USD--
2021723,000 USD---175,000 USD--
2020---3.55 M USD108,000 USD411,000 USD-
2019---5.02 M USD70,000 USD25,000 USD-
2018-395,444 USD-1.8 M USD---
2017213,093 USD------
20166.25 M USD------
20157.61 M USD------
20142.2 M USD------

IGC Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

IGC Pharma historical P/E ratio, EBIT, and P/S ratio.

IGC Pharma shares outstanding

The number of shares was IGC Pharma in 2023 — This indicates how many shares 52.58 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IGC Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IGC Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IGC Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IGC Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IGC Pharma Stock splits

In IGC Pharma's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for IGC Pharma.

IGC Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.03 -0.03  (-14.5 %)2025 Q1
3/31/2024-0.04 -0.4  (-890.1 %)2024 Q4
1

IGC Pharma list of shareholders

%
Name
Stocks
Change
Date
2.96746 % Prins (Richard K)2,244,583329,5833/13/2024
2.45196 % Grimaldi (Claudia)1,854,666336,6663/13/2024
11.45062 % Mukunda (Ram)8,661,251951,2513/13/2024
1.07196 % Moran (James P)810,834220,8343/13/2024
0.94908 % BlackRock Institutional Trust Company, N.A.717,884012/31/2023
0.85294 % The Vanguard Group, Inc.645,166012/31/2023
0.42874 % Geode Capital Management, L.L.C.324,296012/31/2023
0.24340 % State Street Global Advisors (US)184,107012/31/2023
0.15430 % Dearborn Partners L.L.C.116,710012/31/2023
0.10163 % Susquehanna International Group, LLP76,87222,32112/31/2023
1
2
3
4
...
5

IGC Pharma Executives and Management Board

Mr. Ram Mukunda64
IGC Pharma President, Chief Executive Officer, Director (since 2005)
Compensation 1.01 M
Ms. Claudia Grimaldi52
IGC Pharma Vice-President, Principal Financial Officer, Chief Compliance Officer, Director (since 2016)
Compensation 320,000
Mr. Richard Prins66
IGC Pharma Independent Chairman of the Board
Compensation 175,000
Congressman James Moran78
IGC Pharma Independent Director
Compensation 100,000
1

Most common questions regarding IGC Pharma

What values and corporate philosophy does IGC Pharma represent?

India Globalization Capital Inc (IGC) represents a strong commitment to innovation, growth, and value creation. With a focus on rapidly expanding markets, IGC leverages its expertise in developing and commercializing transformative products and solutions. The company's corporate philosophy centers around delivering exceptional shareholder value, fostering long-term partnerships, and adhering to the highest standards of corporate governance and ethics. By staying attuned to market trends and continuously enhancing its offerings, IGC stands as a leading player in sectors like cannabis-based therapies, specialty pharmaceuticals, and infrastructure. IGC's dedication to excellence and strategic approach underscores its mission to enhance the lives of millions through pioneering technologies and forward-thinking strategies.

In which countries and regions is IGC Pharma primarily present?

India Globalization Capital Inc (IGC) is primarily present in India and the United States. With its headquarters in Bethesda, Maryland, USA, IGC operates in various states across India and has a significant presence in its home country. The company focuses on developing and commercializing cannabis-based pharmaceutical and natural wellness products, as well as providing services to the telecommunications and infrastructure sectors. As a global player, IGC aims to leverage its expertise and strategic partnerships to expand its presence in other regions and countries, capitalizing on emerging market opportunities worldwide.

What significant milestones has the company IGC Pharma achieved?

India Globalization Capital Inc (IGC) has achieved several significant milestones over the years. One of the notable achievements is the company's entry into the medical cannabis market. By leveraging its expertise in plant-based therapies and advanced pharmaceutical technologies, IGC has developed a portfolio of cannabinoid-based combination therapies. This pioneering move has positioned the company uniquely in the industry, creating opportunities for substantial growth and market penetration. Moreover, IGC has successfully obtained multiple patents and intellectual property rights, solidifying its position as a leading player in the medical cannabis space. The company's dedication to innovation and strategic partnerships has enabled it to pave the way for novel treatments and carve a niche for itself in the market.

What is the history and background of the company IGC Pharma?

India Globalization Capital Inc. (IGC) is a prominent company founded in 2005. The company primarily operates in various sectors like infrastructure, plant extraction, and traditional Chinese medicine. With a vision to become a global leader, IGC focuses on informational technology-related products and services to fulfill evolving market needs. Throughout its history, IGC has successfully developed and commercialized a range of patented therapies, enhancing consumer healthcare experiences and quality of life. The company's commitment to innovation and diversified business portfolio have contributed to its substantial growth and recognition within the industry. IGC continues to strive towards providing cutting-edge solutions and driving positive advancements in various fields of operation.

Who are the main competitors of IGC Pharma in the market?

The main competitors of India Globalization Capital Inc in the market include companies such as Canopy Growth Corporation, Aurora Cannabis Inc, and Tilray Inc. These companies operate in the same industry and compete with India Globalization Capital Inc in areas such as cannabis-based pharmaceuticals, and alternative therapies and treatment solutions. India Globalization Capital Inc aims to differentiate itself through its proprietary intellectual property and innovative approaches in the market. However, it faces strong competition from these established players who also have a significant market presence and drive advancements in the industry.

In which industries is IGC Pharma primarily active?

India Globalization Capital Inc is primarily active in the industries of infrastructure, real estate, and pharmaceuticals.

What is the business model of IGC Pharma?

The business model of India Globalization Capital Inc (IGC) revolves around various sectors, including infrastructure, technologies, and pharmaceuticals. IGC primarily focuses on the development and commercialization of cannabis-based therapies to address various medical conditions. By leveraging their in-house research and expertise, IGC aims to create innovative cannabis formulations that can potentially improve patient outcomes and quality of life. Additionally, the company also engages in the leasing of heavy equipment, mining exploration, and reclamation of high-grade iron ore to generate sustainable revenue. Through their diversified business segments, IGC strives to deliver value to its shareholders and contribute to the evolving medical and infrastructure sectors.

What is the P/E ratio of IGC Pharma 2024?

The IGC Pharma P/E ratio is -1.58.

What is the P/S ratio of IGC Pharma 2024?

The IGC Pharma P/S ratio is 15.25.

What is the AlleAktien quality score of IGC Pharma?

The AlleAktien quality score for IGC Pharma is 4/10.

What is the revenue of IGC Pharma 2024?

The IGC Pharma revenue is 1.35 M USD.

How high is the profit of IGC Pharma 2024?

The IGC Pharma profit is -13 M USD.

What is the business model of IGC Pharma

India Globalization Capital Inc. is a diversified company that operates in various industries including construction and infrastructure, heavy industry, agricultural and food production, as well as dietary supplements.

What is the IGC Pharma dividend?

IGC Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does IGC Pharma pay dividends?

The dividend cannot currently be calculated for IGC Pharma or the company does not pay out a dividend.

What is the IGC Pharma ISIN?

The ISIN of IGC Pharma is US45408X3089.

What is the IGC Pharma WKN?

The WKN of IGC Pharma is A1T87A.

What is the IGC Pharma ticker?

The ticker of IGC Pharma is IGC.

How much dividend does IGC Pharma pay?

Over the past 12 months, IGC Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGC Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of IGC Pharma?

The current dividend yield of IGC Pharma is .

When does IGC Pharma pay dividends?

IGC Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IGC Pharma?

IGC Pharma paid dividends every year for the past 0 years.

What is the dividend of IGC Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IGC Pharma located?

IGC Pharma is assigned to the 'Industry' sector.

Wann musste ich die Aktien von IGC Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IGC Pharma from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did IGC Pharma pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of IGC Pharma in the year 2023?

In the year 2023, IGC Pharma distributed 0 USD as dividends.

In which currency does IGC Pharma pay out the dividend?

The dividends of IGC Pharma are distributed in USD.

All fundamentals about IGC Pharma

Our stock analysis for IGC Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IGC Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.